The most promising treatments for melanoma patients are combinations of BRAF (vemurafenib, dabrafenib, encorafenib) and MEK inhibitors (cobimetinib, trametinib, binimetinib); however, acquired resistance to treatments develops in a large number of melanoma patients, which strengthens the significance of new therapeutic targets to improve patient survival [45,46,47]. The gene discussed is BRAF; the disease is melanoma.